Shah, Nina
Aiello, Jack
Avigan, David E
Berdeja, Jesus G
Borrello, Ivan M
Chari, Ajai
Cohen, Adam D
Ganapathi, Karthik
Gray, Lissa
Green, Damian
Krishnan, Amrita
Lin, Yi
Manasanch, Elisabet
Munshi, Nikhil C
Nooka, Ajay K
Rapoport, Aaron P
Smith, Eric L
Vij, Ravi
Dhodapkar, Madhav
Clinical trials referenced in this document:
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1007/s12325-022-02226-x
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
https://doi.org/10.1200/jco.20.01370
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma
https://doi.org/10.1007/s40262-023-01232-8
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
https://doi.org/10.1007/s00432-020-03365-w
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas
https://doi.org/10.1136/bmjopen-2024-085364
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
https://doi.org/10.1200/jco.21.02815
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
https://doi.org/10.1200/jco.2024.42.16_suppl.7500
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
https://doi.org/10.1200/jco-24-02266
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).
https://doi.org/10.1200/jco.2023.41.16_suppl.e20005
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).
https://doi.org/10.1200/jco.2023.41.16_suppl.e20005
Documents that mention this clinical trial
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8031
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.
https://doi.org/10.1200/jco.2024.42.16_suppl.7527
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
https://doi.org/10.1200/jco.2023.41.16_suppl.8032
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
https://doi.org/10.1200/jco.2024.42.16_suppl.7529
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-025-03479-y
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
https://doi.org/10.1186/s13045-022-01301-8
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
https://doi.org/10.1200/jco.2023.41.16_suppl.8010
Documents that mention this clinical trial
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
https://doi.org/10.1200/jco.2023.41.16_suppl.8009
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
https://doi.org/10.1200/jco.22.00842
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
https://doi.org/10.1136/jitc-2023-006684
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1200/jco-25-00760
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s12325-025-03479-y
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
https://doi.org/10.1200/jco.22.00690
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma
https://doi.org/10.1136/jitc-2022-006325
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.8041
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma
https://doi.org/10.1136/jitc-2025-013986
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8036
Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.8020
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2024.42.16_suppl.7517
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.8033
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8034
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
https://doi.org/10.1200/jco.2023.41.16_suppl.8011
Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.
https://doi.org/10.1200/jco.2024.42.16_suppl.7540
Documents that mention this clinical trial
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
https://doi.org/10.1200/jco.2023.41.16_suppl.8008
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.e20021
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01168-y
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
5 Multiple myeloma flow cytometry panel validated for clinical monitoring of patients
https://doi.org/10.1136/jitc-2020-sitc2020.0005
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
https://doi.org/10.1200/jco.2023.41.16_suppl.8006
Assessment of health-related quality of life (HRQoL) in triple-class–exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.e23185
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
https://doi.org/10.1200/jco.24.01008
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Documents that mention this clinical trial
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734